Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

palbociclib

28th Oct 2025

Plain language summary of POLARIS: real-world palbociclib effectiveness and life quality impact

Screenshot of a summary article on palbociclib treatment for advanced/metastatic breast cancer in older patients, with key findings, how-to guide for downloading, and publication details.
19th Sep 2025

Plain language summary looking at palbociclib treatment for advanced breast cancer in older patients

22nd Apr 2025

Plain language summary: Palbociclib plus an aromatase inhibitor for HR+/HER2– metastatic breast cancer with lung or liver spread

This summary is about a study that was published in the medical journal The Oncologist in July 2023. The combination of palbociclib with an aromatase inhibitor (AI) was approved by the FDA in 2015 as a treatment for people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer(MBC). However, the effectiveness of palbociclib in African–Americans with MBC is not well studied. The goal of this study was to find out whether adding palbociclib to an AI helped African–Americans with HR+/HER2− MBC live longer.
30th Apr 2024

A plain language summary looking at the palbociclib/aromatase inhibitor treatment combination in African-Americans with metastatic breast cancer (MBC)

This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptor-positive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines – palbociclib and an aromatase inhibitor – compared with taking an aromatase inhibitor alone.
30th Apr 2024

Palbociclib plus an aromatase inhibitor for older patients with metastatic breast cancer

This is a summary of an article that reported results of a study using data from two phase 3 clinical trials called “PALOMA-2” and “PALOMA-3.” Both PALOMA-2 and PALOMA-3 trials included women with HR+/HER2− advanced breast cancer. HR+/HER2− breast cancer means the breast cancer cells of these women have receptors for female sex hormones and little or no HER2 receptors.Both PALOMA trials tested the effect of adding a medication called palbociclib (brand name, Ibrance®) to a hormone therapy. Hormone therapy, also known as endocrine therapy, is a treatment that blocks or removes hormones that cause cancer cells to grow and divide. In both trials, women took endocrine therapy with either palbociclib or a placebo.
2nd Nov 2023

A plain language summary of the PALOMA-2 and PALOMA-3 studies: the effects of adding palbociclib to endocrine therapy to treat advanced breast cancer

12th Apr 2023

Plain Language Summary: a real-world database analysis on prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy